Global Crossing Airlines orders 200 Eve eVTOL aircrafts
Global Crossing Airlines Group, Inc. has signed an Letter of Intent to order up to 200 of Eve UAM, LLC’s eVTOL aircraft, with deliveries expected to start in 2026.
Credit: Eve UAM, LLC
Eve UAM, LLC (Eve), an Embraer S.A. (Embraer) company, and Global Crossing Airlines Group, Inc. (GlobalX) have signed a Letter of Intent (LoI) to order up to 200 of Eve’s electric vertical take-off and landing aircraft (eVTOL). This potential sale is included in Eve’s current order backlog of up to 1,785 eVTOLs. The company expects to start the deliveries in 2026.
The agreement also enables a promising partnership that intends to explore the development of an ecosystem to scale Urban Air Mobility (UAM) and reinforces the Concept of Operations (CONOPS) in Miami-Dade International Airport (MIA). GlobalX’s expertise as a flag airline will contribute not only to the formulation of the infrastructure needed to permit eVTOL flights, but also the deployment of Eve’s aircraft throughout their network.
“We are honoured to be working with Eve Air Mobility and believe their affiliation with Embraer ensures Eve will be the best positioned eVTOL OEM. These eVTOLs will enable us to expand our market throughout south Florida, bringing our customers to their flights at MIA and FLL, as well as local flying within Key West and all of the Keys, Naples, and Palm Beach. This will help extend and expand our brand,” commented Ed Wegel, Chair and CEO of GlobalX.
Andre Stein, co-CEO of Eve added: “We are delighted with this partnership with GlobalX, which will maximise our efforts to structure UAM operations. Their experience as an airline will contribute to the expansion of Eve’s eVTOL deployment in North America. The partnership also ensures both companies’ commitment to delivering sustainable UAM and providing the community with better and faster solutions.”
The completion of the transactions contemplated by the LoI is subject to the execution of definitive agreements and receipt of all necessary regulatory approvals.